StockData
Olema Oncology, Inc. logo

Olema Oncology, Inc. (OLMA) company profile

OLMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$7.22−0.14 (-1.90%)

Close on Nov 17, 2026Market cap $631.73MP/E –Yield –

About Olema Oncology

Pharmaceutical Preparations, SIC 2834

Olema is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for breast cancer and other hormone-driven cancers. The company's lead investigational candidate is palazestrant, an oral small molecule acting as a complete estrogen receptor antagonist and selective estrogen receptor degrader. Olema is advancing palazestrant in late-stage clinical trials both as a single agent and alongside approved targeted medicines for patients with advanced or metastatic breast cancer. A second clinical-stage candidate, OP-3136, functions as a selective inhibitor of KAT6 for breast cancer and other solid tumors. Olema does not currently have approved products or commercial sales, serving patients through clinical trials.

The company operates without internal manufacturing facilities, relying entirely on third-party contract organizations for drug production and supply. Olema conducts clinical studies in collaboration with pharmaceutical partners such as Novartis and Pfizer across target populations primarily in the United States and Europe. The provided text does not state the company's specific headquarters location.

Summary of the business section of Olema Oncology's latest annual report, written by StockData.

Company profile

Company

Legal name
Olema Oncology, Inc.
Headquarters
San Francisco, CA
Address
780 Brannan Street 94103
Phone
(415) 651-3316
Website
olema.com
Employees
131, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, New Jersey

Stock & identifiers

Ticker
OLMA
Exchange
Nasdaq
IPO date
Nov 19, 2020
Shares outstanding
87M, Aug 6, 2026
Public float
$243.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1750284
CUSIP
68062P106
ISIN
US68062P1066
FIGI
BBG00T5JMRT4
Share class FIGI
BBG00T5JMRV1
EIN
30-0409740

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sean BohenPRESIDENT AND CEO, Director237,650
Jason O'ByrneCHIEF FINANCIAL OFFICER–
Shawnte MitchellCHIEF LEGAL OFFICER233
Sasha Lu AustinVP of Finance and Controller4,488
Naseem ZojwallaCHIEF MEDICAL OFFICER103,997
David C. MylesCH. DISCOV. & NON-CLIN DEV OFF687,607
Shane William Charles KovacsCH. OPERATING & FINANCIAL OFF.139,727
Cyrus HarmonDirector819,798
Prakash RamanDirector–
Value Fund L. P. BiotechnologyDirector2,906,659
Partners OS Ltd. BVFDirector447,526
Ii Gp Llc BvfDirector623,707
Value Trading Fund OS LP BiotechnologyDirector3,684,068
Ian T. ClarkDirector0
Cynthia M. ButittaDirector83,876
Andrew RappaportDirector385,965
J. Scott GarlandDirector–
Mark N. LampertDirector2,103,522
I. Gp Llc BvfDirector–
Inc/Il BvfDirector2,103,522
Yi LarsonDirector–
Gp Holdings Llc BvfDirector–
Partners L. P/Il BvfDirector–
Value Fund Ii Lp BiotechnologyDirector2,523,265
Sandra HorningDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.18M$25.16M$1.97M$1020–
FY2024$8.13M-$4.60M$3.63M$238–
FY2023$3.15M$22.26M$1.39M$573–
FY2022$5.99M-$3.27M$2.26M$5–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Sean Bohen, M.D., Ph.D.
President and Chief Executive Officer
$699.92K–$2.00M$461.90K$15.17K$3.18M-61%
Shane Kovacs
Chief Operating and Financial Officer
$562.64K–$985.60K$324.93K$15.17K$1.89M-56%
Shawnte Mitchell, J.D.
Chief Legal Officer and Corporate Secretary
$391.88K$50.00K$1.39M$207.90K$14.98K$2.05M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 19, 2020
Offer price
$19.00
Securities offered
11,000,000
Gross proceeds
$209.00M
Exchange
Nasdaq
First trading day
Nov 19, 2020
First-day close
$49.00+157.9%
Lock-up ends (est.)
May 18, 2021

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of January 31, 2026, we had 131 employees, all of whom were full time, consisting of clinical, research, operations, regulatory, and administrative personnel.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?